{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:34:11Z","timestamp":1794072851837,"version":"4.8.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The dilemma of whether to treat elderly patients with diffuse large B-cell lymphoma (DLBCL) with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone+rituximab) is often faced by clinicians. We conducted a systematic review assessing the impact of R-CHOP DI on DLBCL survival outcomes, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines. We searched MEDLINE, EMBASE, and Cochrane CENTRAL for studies with \u2265100 patients treated with R-CHOP\/R-CHOP\u2013like therapies published from January 2002 through November 2020. Studies were included if they reported the impact of R-CHOP DI on survival outcomes. We screened records, extracted data, and reviewed all the studies for quality and statistical appraisal. Of 380 screened records, 13 studies including 5188 patients were reviewed. DI was often calculated as the ratio of the cumulative delivered dose of prespecified drug(s) to the cumulative planned dose multiplied by a time-correction factor. Lower DI (intended or relative) was associated with inferior survival in 7 of 9 studies reporting crude survival analyses. Multivariable analysis using DI as a covariate was performed in 10 studies. Six showed an association (P &amp;lt; .05) with adjustment for other covariates, and 4 did not. Most studies and those larger studies of higher quality showed poorer outcomes associated with reduced DI. In subgroups aged \u226580 years, survival was not consistently affected by reduced DI. DI-specific randomized trials are warranted, but these data support full-dose R-CHOP in elderly and fit patients aged &amp;lt;80 years with DLBCL, but not in those aged \u226580 years, where dose-reduced R-CHOP does not appear to compromise survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004665","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T08:33:15Z","timestamp":1620462795000},"page":"2426-2437","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":71,"title":["Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-4297","authenticated-orcid":false,"given":"Edward J.","family":"Bataillard","sequence":"first","affiliation":[{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare National Health Service Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia;"},{"name":"Division of Internal Medicine, Medical School, University of Western Australia, Crawley, WA, Australia;"},{"name":"Linear Clinical Research, Nedlands, WA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Oxford Cancer and Haematology Centre, Oxford University Hospitals National Health Service Foundation Trust, Headington, Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"4","key":"2021050715350026500_B1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"2021050715350026500_B2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021050715350026500_B3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021050715350026500_B4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2018.05.006","article-title":"Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study","volume":"99","author":"Juul","year":"2018","journal-title":"Eur J Cancer"},{"issue":"27","key":"2021050715350026500_B5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021050715350026500_B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2021050715350026500_B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: an analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Heal. Inf. Libr. J"},{"issue":"1","key":"2021050715350026500_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"3","key":"2021050715350026500_B9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"2021050715350026500_B10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00277-018-3437-z","article-title":"Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?","volume":"97","author":"M\u00f6rth","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"2021050715350026500_B11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"issue":"3","key":"2021050715350026500_B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hon.2732","article-title":"Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma","volume":"38","author":"Nagata","year":"2020","journal-title":"Hematol Oncol"},{"issue":"8","key":"2021050715350026500_B13","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2019.234435","article-title":"Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma","volume":"105","author":"Lee","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2021050715350026500_B14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4143\/crt.2014.339","article-title":"Reduced dose intensities of doxorubicin in elderly patients with DLBCL in rituximab era","volume":"48","author":"Ha","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"6","key":"2021050715350026500_B15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/joim.12889","article-title":"Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age","volume":"285","author":"Eyre","year":"2019","journal-title":"J Intern Med"},{"issue":"3","key":"2021050715350026500_B16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cam4.2008","article-title":"The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients","volume":"8","author":"D\u0142ugosz-Danecka","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"2021050715350026500_B17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/10428194.2017.1365856","article-title":"The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL\u2014comparative study","volume":"59","author":"Vidal","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2021050715350026500_B18","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00432-020-03279-7","article-title":"Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"146","author":"Yamamoto","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2021050715350026500_B19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma","volume":"28","author":"Terada","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2021050715350026500_B20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4143\/crt.2020.626","article-title":"Prognostic impact of age at the time of diagnosis in Korean patients with diffuse large B-cell lymphoma in the rituximab era: a single institution study","volume":"53","author":"Hwang","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"11","key":"2021050715350026500_B21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-miniCHOP compared with subcutaneous rituximab-miniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021050715350026500_B22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.17250","article-title":"Clinical characteristics and outcomes among 2347 patients aged \u226585 years with major lymphoma subtypes: a Nordic Lymphoma Group study","volume":"192","author":"W\u00e4sterlid","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2021050715350026500_B23","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021050715350026500_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.51.1","article-title":"Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma","volume":"51","author":"Yamaguchi","year":"2011","journal-title":"J Clin Exp Hematop"},{"issue":"11","key":"2021050715350026500_B25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","author":"Hryniuk","year":"1984","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021050715350026500_B26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021050715350026500_B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/9\/2426\/1806927\/advancesadv2021004665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/9\/2426\/1806927\/advancesadv2021004665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T08:33:55Z","timestamp":1620462835000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/9\/2426\/475898\/Impact-of-R-CHOP-dose-intensity-on-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,5,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004665","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]}}}